Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lynne Brum Insider Profile
4 Followers
Lynne Brum, VP, Planning and Corporate Com at Yield10 Bioscience, holds 140.00K shares in Yield10 Bioscience (Ticker: YTEN), holds 53.00K shares in Vertex Pharmaceuticals (Ticker: VRTX).
Lynne Brum has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Lynne Brum holds in companies
Most Profitable Insider Trade
The most profitable trade made by Lynne Brum
Lynne Brum's Trading History
Yield10 Bioscience
Feb 16, 2024
VP, Planning and Corporate Com
Uninformative Buy
30.00K
$168.00K
Vertex Pharmaceuticals
―
VP, Strategic Communications
―
$24.84M
List of latest transactions for each holding click on a transaction to see Lynne Brum's performance on stock
You May Also Like
Lynne Brum insider profile FAQ
What is the percentage of profitable transactions made by Lynne Brum?
The percentage of profitable transactions made by Lynne Brum is ―.
What is the average return per transaction made by Lynne Brum?
The average return per transaction made by Lynne Brum is ―.
What stocks does Lynne Brum hold?
Lynne Brum holds: YTEN, VRTX stocks.
What was Lynne Brum’s latest transaction?
Lynne Brum latest transaction was an Uninformative Buy of $30.00K.
What was Lynne Brum's most profitable transaction?
Lynne Brum’s most profitable transaction was an Informative Buy of YTEN stock on June 23, 2015. The return on the trade was -80.70%.
What is Lynne Brum's role in Yield10 Bioscience?
Lynne Brum's role in Yield10 Bioscience is VP, Planning and Corporate Com.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.